Home｜General Biologicals Corporation

All-in-One Molecular System - GBC AIO M160

English 繁體中文

Our use of cookies

We use cookies and other technologies to improve our website. In addition to necessary cookies, we would like to use cookies (1) to understand how our website is used and performs, including cross-site statistics, (2) to provide you with additional features and personalization settings (3) to provide you with social media interactions, and (4) for targeting and marketing purposes. By clicking "Accept All", you agree to the use of all cookies and corresponding data processing, which may include your browser information and IP address, as well as the disclosure of personal data to third parties, as described in our Cookie Privacy Policy . For details, settings and withdrawal of consent, please click "Cookie Policy".

Reject All

Accept All

Reveal. Better Life.

Creating and manufacturing state-of-the-art diagnostics and healthcare technologies that are affordable to all, GBC is a dedicated force in the advancement of global health.

Over 80 Products in Our Range

Scientific Minds Never Think Alike

One only has to look at human genes—and how they can now be sequenced in hours as opposed to months—to understand the remarkable progress the scientific community makes by encouraging the brightest minds to think differently, but together.

At GBC, we encourage new perspectives in every field of our research. From diagnostic tools to pharmaceuticals, we work with scientists who bring new perspectives to the creation of groundbreaking healthcare technologies.

PRODUCT PIPELINES

Explore Our R&D

GBC for

Consumer Health

Our patented P113 antimicrobial peptide (AMP) has been approved for safety and effectiveness by the US FDA Phase II and is now being used to create products that significantly enhance people’s quality of life.

With our "oh care" brand offering a range of products from baby care to oral and skin care, we’re not simply designing new healthcare solutions but bringing them to the people who need them.

Explore Consumer Products

Unfold Your Future

Work with GBC to make a real difference to global healthcare

Insights

Stay up-to-date with the latest developments at GBC and the healthcare industry

Explore how GBC is bringing real change to the field of diagnostics and healthcare.

Explore Our Products

Congratulations!
GBC CellBio™ Wins the 2025 Taiwan Excellence Award!

GBC has proudly received the 2025 Taiwan Excellence Award for its fully automated cell sorting system, CellBio™ FX10.

Exploring New Trends in the Field of Medical Technology - Precision Medicine

Recently, the Genetic Nutrition Functional Medicine Association, in collaboration with GBC and Leopard Gene, jointly organized a seminar on "Precision Medicine in Comprehensive Health" that garnered significant attention from the medical and industry sectors.

GBC Starts Carbon Inventory Project to Grasp Carbon Management and Net-Zero Trends

Due to the crisis of global warming and climate change, the Taiwanese government responded to international initiatives in 2022 by actively declaring a commitment to achieve net-zero emissions by 2050. In February 2023, they passed the Climate Change Response Act and established a carbon trading market in August of the same year. In 2024, carbon fees were imposed on domestic carbon-intensive industries and major carbon emitters to incentivize companies to reduce emissions. Particularly significant was the commencement in October 2023 of the European Union's Carbon Border Adjustment Mechanism (CBAM) transitional phase, which required the declaration of product carbon emissions-related information. Starting in 2026, CBAM certificates will be levied, impacting an estimated over one hundred thousand export supply chain companies across Taiwan.

GBC CellBio™ Technology Platform received the Bronze Award at the National Pharmaceutical Technology & Research Development Awards.

GBC was nominated for the 112th National Pharmaceutical Technology & Research Development Awards jointly hosted by Taiwan's Food and Drug Administration of the Ministry of Health and Welfare and the Industrial Development Bureau of the Ministry of Economic Affairs for its CellBio™technology platform product.

Featured Insights

November 27, 2024, HsinchuGBC Corporation (referred to as “GBC,” stock code: 4117), a leader in precision medicine, has been honored with the 33rd "2024 Taiwan Excellence Award" for its fully automated CellBio™ Circulating Tumor Cell (CTC) Detection System. Recognized for its high precision, efficiency, and non-invasive approach, the product is revolutionizing early cancer detection and monitoring, making a profound impact on global cancer screening practices. This accolade underscores GBC's outstanding R&D and manufacturing capabilities in the field of precision medicine.The CellBio™ Circulating Tumor Cell (CTC) Detection System excels with high capture rates and detection precision for cancer cells. It can process up to 10 samples simultaneously, significantly reducing detection time and minimizing manual intervention. By extracting only 7.5 milliliters of blood, the system effectively isolates and captures rare cancer cells in a non-invasive manner, accurately identifying the number of cancer cells in the blood and monitoring their dynamic changes. With a cancer cell capture rate exceeding 90%, this innovation provides a more reliable solution for early cancer screening. It also assists doctors in health monitoring during treatment, particularly in tracking the effectiveness of treatments and the risk of recurrence for known cancer patients, offering accurate and intuitive data for enhanced medical care.In its commitment to expanding Taiwan’s cancer screening market, GBC has signed an exclusive agreement with Fubon Life Insurance to offer the "Next-Generation myCTC Blood Circulating Tumor Cell Detection" service to new policyholders. As of October 2024, over 25,000 cases have been completed under this collaboration. GBC continues to deepen its partnership with Fubon and plans to introduce new products while actively seeking collaboration opportunities with hospitals and clinics across Taiwan. These efforts are expected to positively contribute to the company’s future operations.Looking ahead, GBC is optimistic about the growing market demand for precision medical diagnostics and liquid biopsies. The company is focused on advancing its five core business areas: precision diagnostics, liquid biopsy, CDMO (Contract Development and Manufacturing Organization), diagnostic services, and P113 antimicrobial peptide pharmaceuticals. Leveraging its comprehensive supply chain that spans R&D, manufacturing, sales, and diagnostic services, GBC is steadfast in its mission to “start with diagnostics and collaborate with healthcare partners to protect public health.” The company continues to invest in molecular diagnostics and cancer-related liquid biopsy technologies, aiming to expand its service portfolio and align with the global trend toward precision health.

GBC (4117) announced on the 2nd that it has signed a three-year exclusive distribution agreement with a Brazilian distributor to expand into South America. The main products to be sold include ELISA serum antibody assays, hepatitis A/B/C/D testing assays, as well as CLIA chemiluminescence immunoassay and PCR equipment and related reagents. The Brazilian distributor has already partnered with over 40% of local blood centers, accumulating sales channels with more than 200 laboratories and hospitals. Deliveries are expected to gradually commence from April, boosting GBC's new growth momentum.GBC indicated that its revenue distribution for the first two months of this year was 42% in Taiwan, 13% in the Middle East, and 2% in Southeast Asia. Additionally, besides existing sales in Mexico, this collaboration with the Brazilian distributor is expected to generate sales momentum for GBC's precise testing equipment and reagents, further expanding the company's sales footprint in South America and enhancing its overall international sales strategy.Leveraging the group's integrated operations encompassing research and development, manufacturing, clinical trials, and global distribution, GBC aims to complete and launch its AI park facility in Zhubei in the second half of 2024. Continual negotiations with international distributors will also contribute to expanding the operational scale of precise testing and liquid biopsy services, complementing resources with its existing Zhubei factory in the Hsinchu Science Park and bolstering opportunities for international business development.Looking ahead, GBC is optimistic about the increasing market demand in precision medical testing and liquid biopsy fields, actively enhancing its core business areas including precise testing, liquid biopsy, CDMO (Contract Development and Manufacturing Organization), testing services, and P113 antimicrobial peptide drugs. Participation in key international biotechnology and medical exhibitions will further raise the visibility of the GBC brand and promote order intake for precise testing and liquid biopsy services, thereby creating favorable growth prospects for GBC's future operations.

November 21, 2023, Hsinchu, Precise Medical Manufacturer GBC Co., Ltd. (referred to as "GBC" with stock code: 4117) was nominated for the 112th National Pharmaceutical Technology & Research Development Awards jointly hosted by Taiwan's Food and Drug Administration of the Ministry of Health and Welfare and the Industrial Development Bureau of the Ministry of Economic Affairs for its CellBio™technology platform product. Today, at the award ceremony, GBC was honored to receive the "Bronze Award in the Medical Devices Category," highlighting the company's continuous enhancement of research and development capabilities and competitive advantages over the years. Alongside its commitment to improving the entire supply chain encompassing research, development, manufacturing, sales, and inspection services, GBC aims to establish a cornerstone for sustained development within the group.The "National Pharmaceutical Technology & Research Development Awards" is a national-level recognition program categorized into three main sections based on the nature of the research and development products: pharmaceuticals, medical devices, and manufacturing technology. It aims to reward companies that have made outstanding contributions to the research and development of new drugs and related manufacturing technologies. This initiative encourages more companies to showcase their technological advancements in emerging pharmaceuticals or medical devices, thereby elevating Taiwan's pharmaceutical manufacturing industry standards and clinical trial quality. With GBC's establishment as a professional testing reagent manufacturing service company contributing to the government's ten-year plan for hepatitis prevention and control, it has continuously enhanced its team's research capabilities and competitive advantages over the years. This effort has facilitated the group's standout performance among numerous high-quality enterprises, resulting in the recognition and awarding of the "Bronze Award in the Medical Devices Category" as a testament to GBC's contributions. Mr. Frank Lin, President of GBC stated that the group's proprietary iFiltration™ technology has not only secured patents in Taiwan but has also obtained novel patents in Japan, China, and other countries. Leveraging the microfiltration membrane separation technique of iFiltration™, it effectively isolates cells, achieving a recovery rate of over 97% for circulating tumor cells (CTCs). This technology serves as the core for GBC's award-winning manual blood cell counting device, a part of the CellBio™ technology platform. The said product requires only a 7.5mL blood sample and can capture CTCs within two hours, enabling the detection of circulating tumor cells in the blood, monitoring dynamic changes in cancer cells within the body. This serves the purpose of early cancer detection, postoperative recurrence monitoring, and tracking treatment effectiveness. It offers a more precise and efficient screening method, aiding patients in receiving more accurate medical care. Looking ahead, GBC will continue to develop comprehensive diagnostic services by actively investing in research and development of related technologies such as molecular diagnostics, liquid biopsies, cancer diagnostics, and more. The company aims to enhance its five core business areas: precision testing, liquid biopsies, CDMO, testing services, and P113 antimicrobial peptide drugs. Moreover, GBC is planning to construct a large-scale office building in the Hsinchu AI Intelligent Park in Zhubei, featuring nine centers focusing on energy conservation, carbon reduction, and establishing a presence in the broader health sector. This project is expected to be completed and operational by the latter half of 2024. The goal is to complement the existing Zhubei factory located in the Hsinchu Science Park, integrating resources to optimize the layout in the field of comprehensive health. This strategic move aims to assist GBC in expanding its international market and business development opportunities.

GBC introduces two CellBio CTC cancer detection devices at AACCGBC introduces GB RealQuant AIO Sample-To-Results automated molecular system at AACCHSINCHU, Taiwan – July 24, 2023 – Taiwanese IVD (In-Vitro Diagnostic) manufacturer General Biologicals Corporation (GBC) today unveiled two CellBio™ circulating tumor cell (CTC) cancer detection products at the American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo, being held July 23-27 in Anaheim, California.GBC is officially launching its award-winning brand in the U.S. market with a highly competitive niche IVD (in vitro diagnostics) device and assay.GBC’s two CTC detection systems are viewed globally at the forefront of science and are used for early detection, treatment validation and therapy monitoring with rapid, accessible and affordable diagnostic solutions. The CellBio platform, which uses GBC proprietary iFiltration™ technology, provides positive control, is designed to ensure the filtration efficiency is accurate, and has led to Taiwan’s first standardized CTC system. The technology is patented and won the 2022 Taiwan National Innovation Award.“CellBio focuses on the detection, monitoring and treatment of cancer metastasis. The goal of GBC is to revolutionize the detection and treatment of cancer through its unique CTC technology and complementary therapeutics platform CellBio,” said Frank Lin, the President of GBC. “More than 10 million patients die from cancer each year and more than 90 percent of the deaths are attributed to metastasis. Currently, there are no approved therapies that specifically target the metastatic process. Targeting CTCs with novel therapeutics could likely have a significant impact on cancer metastases and patient outcome.”Among the advantages of the CellBio system are detection from 7.5-mL blood samples with high specificity, sensitivity, and cancer capture rate, complete within 90 minutes. The system applies to cancer screening, diagnosis, monitoring and prognosis; provides optimal treatment; and improves the quality of life for patients. The number of CTCs in the blood can be completely monitored during the non-invasive sampling process, and the capture rate of more than 90 percent of cancer cells is better than the industry norm.The CellBio FX10, can work with 10 samples at a time with a full-color touch screen, while CellBio a2000 can detect 2 samples at a time in small-space labs. GBC has already accumulated more than 8,000 samples, resulting in good efficacy. According to BBC research, the global liquid biopsy market for cancer applications was US$1.7 billion in 2020 and is expected to grow at a compound annual growth rate of 50.7 percent, reaching a forecasted size of US$13.6 billion by 2025. Major market segments include bladder, breast, colon, gynecology-related cancers, lung cancer, pan-cancer and prostate cancer.In addition to CTC systems, GBC introduces the Samples-To-Results automated All-in-One molecular system, GB RealQuant® AIO. The system consolidates extraction, amplification and detection in one easy-to-use integrated instrument, providing fast and reliable results within 2 hours with high flexibility. The system works with all GB RealQuant HBV, HCV, and HPV Kits.For more information about GBC, visit www.gbc.com.tw Media contactsFrank Lin, GBC President, (03)577-9221, frank.lin@gbc.com.tw

TAIPEI, Taiwan, Aug. 19, 2022 — General Biologicals Corporation (GBC), a Taiwanese In-Vitro Diagnostic (IVD) specializing in Precision Diagnostics was honored with the "2022 HR Asia Best Companies to Work for in Asia". In all, 26,200 employees from 330 Taiwanese companies took part in HR Asia's proprietary Total Engagement Assessment Model - ranking their own employers on metrics ranging from workplace happiness and team cohesion to employee advocacy and continued job motivation. The top 97 companies who made the cut off point this year are then named HR Asia Best Companies to work for in Asia 2022 for the Taiwanese market."HR Asia Best Companies to Work for in Asia is the only award that is judged solely by the nominees' employees - making this the most transparent award of its kind. Equally important, with 15 markets, and over 400,000 surveys done each year - the program is also the most extensive awards for employee engagement and workplace excellence across the region", says William Ng, group publisher of Business Media International, the owner of HR Asia.Mr. Frank Lin, President of GBC, said that the group believes that talents are the cornerstone of the sustainable development of the enterprise. Since its establishment, it has adhered to the value-oriented development of all colleagues and the group, including various company benefits, focusing on the physical and mental health of colleagues, respecting the positions of colleagues in various departments, and maintaining colleagues at any time. Coordinating communication and feedback and encouraging the provision of resources for professional training of talents, etc., this award affirms the Group's progress towards a happy enterprise and sustainable development goals. About General Biologicals CorporationFounded in 1984, General Biologicals Corporation (GBC) is a developer and manufacturer of diagnostics and pharmaceutical products headquartered in Taiwan. GBC develops high-quality in-vitro diagnostics for doctors to make clinical decisions in the areas of hepatitis, tumor markers, retrovirus, fertility, thyroid, and steroids. The company also provides anti-bacterial peptides (US FDA Clinical Trial Phase IIb) in the areas of pharmaceutical, cosmetics, and oral products.

/16

ERUOMEDLAB 2025

The 26th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine (EUROMEDLAB 2025), combined with the 49th Annual Congress of the Royal Belgian Society of Laboratory Medicine, will take place from May 18 to 22, 2025, in Brussels, Belgium. The conference is jointly organized by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), and the Royal Belgian Society of Laboratory Medicine.